Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Oct;66(10):1356-62.
doi: 10.1136/ard.2006.066662. Epub 2007 Feb 9.

Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score

Sjoerd M van der Kooij  1 , Jeska K de Vries-Bouwstra, Yvonne P M Goekoop-Ruiterman, Derkjen van Zeben, Pit J S M Kerstens, Andreas H Gerards, Johannes H L M van Groenendael, Johanna M W Hazes, Ferdinand C Breedveld, Cornelia F Allaart, Ben A C Dijkmans
Affiliations
Randomized Controlled Trial

Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score

Sjoerd M van der Kooij et al. Ann Rheum Dis. 2007 Oct.

Abstract

Objectives: To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years.

Methods: In groups 1 and 2 of the BeSt study, 244 RA patients were initially treated with MTX 15-25 mg/week. Patients who discontinued MTX because of insufficient clinical response (disease activity score, DAS >2.4) or toxicity were classified as "MTX failures." In group 1, these patients switched to sulfasalazine (SSA), then leflunomide and finally to MTX + infliximab (IFX). In group 2, "MTX failures" added SSA to MTX, then hydroxychloroquine (HCQ), then prednisone, and eventually switched to MTX + IFX. "MTX successes" were patients who achieved a DAS </=2.4 after 2 years while still on MTX monotherapy. Total Sharp/van der Heijde score (TSS) progression from 0-2 years was assessed in "MTX failures" versus "MTX successes."

Results: After 2 years, 162/244 patients (66%) had discontinued MTX because of insufficient response or toxicity. Of these, 78% also failed on SSA (adding or switching), 87% subsequently failed on leflunomide (in group 1), and 64% on MTX + SSA + HCQ (in group 2). 34 of 48 patients (71%) in groups 1 and 2 were successfully treated with MTX + IFX. After 2 years, regardless of the "success" on subsequent DMARDs, " MTX failures" had a median TSS progression of 3 units (mean 9) versus 1 unit (mean 3) in "MTX successes" (p = 0.007).

Conclusion: After failure on initial MTX, treatment with subsequent conventional DMARDs is unlikely to result in a DAS </=2.4 and allows progression of joint damage.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Professor Dr FC Breedveld did a paid expert testimony for Centocor in 1996 and was a paid speaker in a Schering Plough sponsored symposia. Dr CF Allaart was a paid speaker in a Schering Plough sponsored symposium in 2006.

Comment in

References

    1. Scott D L, Symmons D P, Coulton B L, Popert A J. Long‐term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 19873291108–1111. - PubMed
    1. Smolen J S, Kalden J R, Scott D L, Rozman B, Kvien T K, Larsen A.et al Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double‐blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999353259–266. - PubMed
    1. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G.et al Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 19991592542–2550. - PubMed
    1. Aletaha D, Smolen J S. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology 2002411367–1374. - PubMed
    1. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen J S. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 200321(Suppl 31)S179–S185. - PubMed

Publication types

MeSH terms